ABMD Abiomed Inc

Price (delayed)

$354.725

Market cap

$16.1B

P/E Ratio

103.72

Dividend/share

N/A

EPS

$3.42

Enterprise value

$15.92B

Abiomed is a publicly-traded medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump. The company is headquartered in Danvers, Massachusetts and has ...

Highlights
Abiomed's equity has increased by 19% YoY
The company's gross profit rose by 18% YoY and by 11% QoQ
ABMD's P/E is 45% above its last 4 quarters average of 72.1 and 37% above its 5-year quarterly average of 76.4
ABMD's EPS is down by 32% since the previous quarter and by 2.6% year-on-year

Key stats

What are the main financial stats of ABMD
Market
Shares outstanding
45.38M
Market cap
$16.1B
Enterprise value
$15.92B
Valuations
Price to earnings (P/E)
103.72
Price to book (P/B)
12.29
Price to sales (P/S)
17.19
EV/EBIT
73.11
EV/EBITDA
65.44
EV/Sales
17.02
Earnings
Revenue
$935.26M
EBIT
$217.79M
EBITDA
$243.32M
Free cash flow
$247.67M
Per share
EPS
$3.42
Free cash flow per share
$5.47
Book value per share
$28.87
Revenue per share
$20.64
TBVPS
$29.52
Balance sheet
Total assets
$1.46B
Total liabilities
$150.87M
Debt
$0
Equity
$1.31B
Working capital
$616.75M
Liquidity
Debt to equity
0
Current ratio
6.45
Quick ratio
5.41
Net debt/EBITDA
-0.72
Margins
EBITDA margin
26%
Gross margin
81.7%
Net margin
16.5%
Operating margin
15.6%
Efficiency
Return on assets
10.8%
Return on equity
12.2%
Return on invested capital
21.7%
Return on capital employed
16.2%
Return on sales
23.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABMD stock price

How has the Abiomed stock price performed over time
Intraday
-0.88%
1 week
-1.79%
1 month
7.96%
1 year
28.46%
YTD
9.42%
QTD
13.65%

Financial performance

How have Abiomed's revenue and profit performed over time
Revenue
$935.26M
Gross profit
$764.15M
Operating income
$146.21M
Net income
$154.41M
Gross margin
81.7%
Net margin
16.5%
Abiomed's operating margin has decreased by 44% YoY and by 42% QoQ
ABMD's net margin is down by 38% since the previous quarter and by 17% year-on-year
The company's operating income fell by 36% QoQ and by 34% YoY
The net income has contracted by 32% from the previous quarter and by 2.7% YoY

Growth

What is Abiomed's growth rate over time

Valuation

What is Abiomed stock price valuation
P/E
103.72
P/B
12.29
P/S
17.19
EV/EBIT
73.11
EV/EBITDA
65.44
EV/Sales
17.02
ABMD's P/E is 45% above its last 4 quarters average of 72.1 and 37% above its 5-year quarterly average of 76.4
ABMD's EPS is down by 32% since the previous quarter and by 2.6% year-on-year
Abiomed's equity has increased by 19% YoY
ABMD's P/B is 13% above its last 4 quarters average of 11.0 but 5% below its 5-year quarterly average of 13.1
The company's revenue rose by 17% YoY and by 10% QoQ
The price to sales (P/S) is 9% higher than the 5-year quarterly average of 15.9 and 6% higher than the last 4 quarters average of 16.4

Efficiency

How efficient is Abiomed business performance
ABMD's return on equity is down by 34% since the previous quarter and by 19% year-on-year
Abiomed's ROA has decreased by 34% from the previous quarter and by 19% YoY
ABMD's return on sales is down by 31% since the previous quarter and by 13% year-on-year
The ROIC has contracted by 28% from the previous quarter and by 13% YoY

Dividends

What is ABMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABMD.

Financial health

How did Abiomed financials performed over time
ABMD's quick ratio is up by 17% year-on-year and by 2.5% since the previous quarter
Abiomed's total assets has increased by 17% YoY but it has decreased by 2.4% from the previous quarter
ABMD's debt is 100% smaller than its equity
Abiomed's equity has increased by 19% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.